Profile
Patrick Chaltin is currently Director at Cytura Therapeutics BV and Managing Partner at Centre for Drug Design & Discovery.
Formerly, Dr. Chaltin was Non-Executive Director at Aratana Therapeutics NV.
Dr. Chaltin earned a doctorate from Katholieke Universiteit Leuven.
Patrick Chaltin active positions
| Companies | Position | Start |
|---|---|---|
Cytura Therapeutics BV
Cytura Therapeutics BV Miscellaneous Commercial ServicesCommercial Services Engages in researching and developing biotechnology | Director/Board Member | - |
Centre for Drug Design & Discovery
Centre for Drug Design & Discovery Investment ManagersFinance Centre for Drug Design & Discovery is an active manager which invests in companies located in Belgium. It participates in seed stage and early stage transactions and focuses on the Health Technology sector. | Private Equity Investor | - |
Former positions of Patrick Chaltin
| Companies | Position | End |
|---|---|---|
Aratana Therapeutics NV
Aratana Therapeutics NV Pharmaceuticals: OtherHealth Technology Develops and markets drugs to treat viral infections in both pet animals and livestock | Director/Board Member | - |
Training of Patrick Chaltin
Experiences
Positions held
Active
Inactive
Listed companies
Private companies
Linked companies
| Private companies | 4 |
|---|---|
Katholieke Universiteit Leuven
Katholieke Universiteit Leuven Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
Aratana Therapeutics NV
Aratana Therapeutics NV Pharmaceuticals: OtherHealth Technology Develops and markets drugs to treat viral infections in both pet animals and livestock | Health Technology |
Cytura Therapeutics BV
Cytura Therapeutics BV Miscellaneous Commercial ServicesCommercial Services Engages in researching and developing biotechnology | Commercial Services |
Centre for Drug Design & Discovery
Centre for Drug Design & Discovery Investment ManagersFinance Centre for Drug Design & Discovery is an active manager which invests in companies located in Belgium. It participates in seed stage and early stage transactions and focuses on the Health Technology sector. | Finance |
- Stock Market
- Insiders
- Patrick Chaltin
















